Clarke Nicole, Germain Pierre, Altucci Lucia, Gronemeyer Hinrich
Department of Cell Biology and Signal Transduction, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC)/CNRS/INSERM/ULP, BP 163, 67404 Illkirch Cedex, C. U. de Strasbourg, France.
Expert Rev Mol Med. 2004 Nov 30;6(25):1-23. doi: 10.1017/S1462399404008488.
Retinoids (derivatives of vitamin A) are signalling molecules that play important roles in cell growth, differentiation and death. Retinoids act through two types of receptors - retinoic acid receptors (RAR alpha, RAR beta and RAR gamma) and retinoid X receptors (RXR alpha, RXR beta and RXR gamma) - which themselves act as ligand-dependent transcription factors. Retinoids are of special interest in cancer research owing to their antiproliferative and cancer-preventative properties. They have been used successfully to cure acute promyelocytic leukaemia (APL) and can suppress carcinogenesis in a variety of tissue types (e.g. skin, lung, breast and oral cancers). Extensive research efforts have been dedicated to elucidating the molecular and cellular networks that are induced by retinoids, and this has recently yielded novel insights into how retinoids can both prevent and combat cancer.
类视黄醇(维生素A的衍生物)是在细胞生长、分化和死亡过程中发挥重要作用的信号分子。类视黄醇通过两种类型的受体发挥作用——维甲酸受体(RARα、RARβ和RARγ)和类视黄醇X受体(RXRα、RXRβ和RXRγ)——它们本身作为配体依赖性转录因子发挥作用。由于其抗增殖和防癌特性,类视黄醇在癌症研究中备受关注。它们已成功用于治疗急性早幼粒细胞白血病(APL),并可抑制多种组织类型(如皮肤癌、肺癌、乳腺癌和口腔癌)的致癌作用。广泛的研究致力于阐明由类视黄醇诱导的分子和细胞网络,最近这为类视黄醇如何预防和对抗癌症带来了新的见解。